Overview
PERCIMEL is an open multicentric study. The purpose of this study is to assess the interest of molecular analysis on circulating tumor DNA in the follow-up of the disease.
Eligibility
Inclusion Criteria:
- locally advanced, operable melanoma
- treated by immunotherapy or anti-BRAF and anti-MEK targeted therapies (stage IIIb, IIIc) or exclusive immunotherapy (stage IV) in an adjuvant situation.
Exclusion Criteria:
- second cancer
- woman who is pregnant, likely to be pregnant or breastfeeding